POWERTECH TECHNOLOGY INC. v. Tessera, Inc. (2011)
green
· 40 citation events
across 6 courts.
Showing the 9 strongest citers on record
(one row per citing case, strongest signal kept).
Treatment trajectory · 2012 → 2026 · click a year to view the case as of then
201220192026
Sort:
By significance ·
Most recent
green
Abbvie Inc. v. Medimmune Limited (2018)
In Powertech Technology Inc. v. Tessera, Inc., the parties disputed whether royalty obligations under a contract were contingent on the validity and infringement of a patent. 660 F.3d 1301, 1308-10 (Fed.
green
First Data Corporation v. Inselberg (2017)
Inc. v. Tessera, Inc., 660 F.3d 1301, 1306 (Fed.
green
Asia Vital Components Co. v. Asetek Danmark A/S (2016)
Inc. v. Tessera, Inc., 660 F.3d 1301, 1306 (Fed.
green
Microsoft Corporation v. Itc (2014)
Inc. v. Tessera, Inc., 660 F.3d 1301, 1308 (Fed.
this court’s rulings in cases coming from the Commission have precedential effect on the parties in related litigation
Id. at 1377.
green
Powertech Technology, Inc. v. Tessera, Inc. (2012)
See Opp. to Mot. to Dismiss, Powertech Technology, Inc. v. Tessera, Inc. (PTI I), Case No. 10-945 (N.D.Cal.), Docket No. 33; Powertech Technology, Inc. v. Tessera, Inc., 660 F.3d 1301, 1304 (Fed.Cir.2011).
green
Dror v. Kenu, Inc. (2019)
Inc. v. Tessera, Inc., 660 F.3d 1301, 1306 (Fed.
See , e.g. , Powertech Technology Inc. v. Tessera, Inc. , 660 F.3d 1301, 1309-1310 (Fed.
See, e.g., Powertech Technology Inc. v. Tessera, Inc., 660 F.3d 1301, 1309-1310 (Fed.Cir.2011), (explaining that in MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118, 135-136 , 127 S.Ct. 764 , 166 L.Ed.2d 604 (2007), the Court stated that the issue of contract interpretation is a merits issue, and not appropriate for a decision on a motion to dismiss under Rule 12(b)(1)). 17 .